Einzeltreffer — DigiBib

Recently, olsalazine a DNA hypomethylating agent was found to inhibit the growth of breast cancer cells. The present study was carried out to evaluate the effects of olsalazine pretreatment in the potentiation of chemosensitivity of gemcitabine for the treatment of hepatocellular carcinoma (HCC). In silico molecular docking was performed to analyze the interaction of olsalazine and gemcitabine with DNMT1 and DNA, respectively, using the AutoDock tools 1.5.6. Cytotoxicity of olsalazine, gemcitabine, and combination were measured on human HePG2 cells using MTT assay. Antiproliferative effects were assessed using animal model of N-nitrosodiethylamine and carbon tetrachloride-induced HCC. Treatment was initiated from 8th week of induction to 11th week and change in body weight, liver weight, and survival rate were measured. Following treatment, blood samples were collected for estimation serum biochemistry. Blood serum was used for the estimation of inflammatory cytokines tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), C-reactive protein [CRP], lactate dehydrogenase (LDH), and P53 levels. Oxidative stress markers were measured in liver tissue homogenates. Histopathology and immunohistochemistry (IHC) were performed on liver sections to detect the morphological changes and P53 expression. Docking analysis revealed the interactions between olsalazine and DNMT1 with a binding energy score of -5.34 and gemcitabine and DNA with a binding energy score of -5.93. Olsalazine pretreatment potentiated the antiproliferative effect of gemcitabine in cell line study. In the group receiving olsalazine pretreatment showed significant reductions in relative liver weight and improved survival rate of gemcitabine treatment group. Serum biochemical markers: serum glutamate pyruvate transaminase, serum glutamic oxaloacetic transaminase, alkaline phosphatase, and bilirubin revealed improved liver functions. Olsalazine pretreatment also reduced the levels of inflammatory markers like CRP, LDH, TNF-α, and IL-6 and oxidative stress markers dose dependently. Histopathology and IHC showed improved liver morphology with potentiated the induction of P53 upon olsalazine pretreatment in combination with gemcitabine. In conclusion, sequential combination of olsalazine and gemcitabine improved the treatment outcomes during the progression of HCC.

Titel:	Olsalazine pretreatment augments chemosensitivity of gemcitabine in hepatocellular carcinoma.
Autor/in / Beteiligte Person:	Sharma, A ; Chhipa, AS ; Verma, S ; Parikh, P ; Patel, S
Link:	Full Text Finder (Volltext)
Zeitschrift:	Journal of biochemical and molecular toxicology, Jg. 38 (2024-06-01), Heft 6, S. e23737
Veröffentlichung:	New York, NY : Wiley, c1998-, 2024
Medientyp:	academicJournal
ISSN:	1099-0461 (electronic)
DOI:	10.1002/jbt.23737
Schlagwort:	Humans Animals Hep G2 Cells Molecular Docking Simulation Male Drug Synergism Rats DNA (Cytosine-5-)-Methyltransferase 1 metabolism Deoxycytidine analogs & derivatives Deoxycytidine pharmacology Gemcitabine Carcinoma, Hepatocellular drug therapy Carcinoma, Hepatocellular pathology Carcinoma, Hepatocellular metabolism Liver Neoplasms drug therapy Liver Neoplasms pathology Liver Neoplasms metabolism
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [J Biochem Mol Toxicol] 2024 Jun; Vol. 38 (6), pp. e23737. MeSH Terms: Deoxycytidine* / analogs & derivatives ; Deoxycytidine* / pharmacology ; Gemcitabine* ; Carcinoma, Hepatocellular* / drug therapy ; Carcinoma, Hepatocellular* / pathology ; Carcinoma, Hepatocellular* / metabolism ; Liver Neoplasms* / drug therapy ; Liver Neoplasms* / pathology ; Liver Neoplasms* / metabolism ; Humans ; Animals ; Hep G2 Cells ; Molecular Docking Simulation ; Male ; Drug Synergism ; Rats ; DNA (Cytosine-5-)-Methyltransferase 1 / metabolism References: J. H. Oh, D. W. Jun, Clin. Mol. Hepatol. 2023, 29(2), 355. ; H. Rumgay, M. Arnold, J. Ferlay, O. Lesi, C. J. Cabasag, J. Vignat, M. Laversanne, K. A. McGlynn, I. Soerjomataram, J. Hepatol. 2022, 77(6), 1598. ; Y. Guo, X. Li, X. Sun, J. Wang, X. Yang, X. Zhou, X. Liu, W. Liu, J. Yuan, L. Yao, X. Li, L. Shen, Int. J. Biol. Sci. 2019, 15(9), 1771. ; S. R. Alberts, J. M. Reid, B. W. Morlan, G. H. Farr Jr., J. K. Camoriano, D. B. Johnson, J. R. Enger, T. E. Seay, G. P. Kim, Am. J. Clin. Oncol. 2012, 35(5), 418. ; V. G. Sorrentino, S. Thota, E. A. Gonzalez, P. Rameshwar, V. T. Chang, J. P. Etchegaray, Pharmaceuticals 2021, 14(7), 641. ; S. Jueliger, J. Lyons, S. Cannito, I. Pata, P. Pata, M. Shkolnaya, O. Lo Re, M. Peyrou, F. Villarroya, V. Pazienza, F. Rappa, F. Cappello, M. Azab, P. Taverna, M. Vinciguerra, Epigenetics 2016, 11(10), 709. ; A. Sharma, R. Vatapalli, E. Abdelfatah, K. Wyatt McMahon, Z. Kerner, A. A. Guzzetta, J. Singh, C. Zahnow, S. B. Baylin, S. Yerram, Y. Hu, N. Azad, N. Ahuja, PLoS One 2017, 12(4), e0176139. ; S. Xu, C. Jiang, R. Lin, X. Wang, X. Hu, W. Chen, X. Chen, T. Chen, J. Exp. Clin. Cancer Res. 2021, 40(1), 373. ; C. Cristalli, M. C. Manara, S. Valente, E. Pellegrini, A. Bavelloni, A. De Feo, W. Blalock, E. Di Bello, D. Piñeyro, A. Merkel, M. Esteller, O. M. Tirado, A. Mai, K. Scotlandi, Front. Endocrinol. 2022, 13, 876602. ; A. B. A. Laranjeira, M. G. Hollingshead, D. Nguyen, R. J. Kinders, J. H. Doroshow, S. X. Yang, Sci. Rep. 2023, 13(1), 5964. ; H. Karimi‐Maleh, N. Erk, Chemosphere 2023, 336, 139268. ; O. Méndez‐Lucio, J. Tran, J. L. Medina‐Franco, N. Meurice, M. Muller, ChemMedChem 2014, 9(3), 560. ; M. Naghitorabi, G. Saki, S. Gharishvandi, Jundishapur J. Nat. Pharm. Prod. 2020, 15(4), e69428. ; M. Asl, J. Asl, M. Naghitorabi, Res. Pharm. Sci. 2021, 16(3), 278. ; A. K. Bakrania, B. C. Variya, S. S. Patel, Front. Pharmacol. 2017, 8, 930. ; S. Marklund, G. Marklund, Eur. J. Biochem. 1974, 47(3), 469. ; M. E. Anderson, Methods Enzymol. 1985, 113, 548. ; H. Ohkawa, N. Ohishi, K. Yagi, Anal. Biochem. 1979, 95(2), 351. ; D. S. Mandlik, S. K. Mandlik, S. Patel, Immunopharmacol. Immunotoxicol. 2021, 43(5), 571. ; N. Aumpan, R.‐K. Vilaichone, P. Nunanan, S. Chonprasertsuk, S. Siramolpiwat, P. Bhanthumkomol, B. Pornthisarn, T. Uchida, V. Vilaichone, A. Wongcha‐Um, Y. Yamaoka, V. Mahachai, PLoS One 2020, 15(10), e0239434. ; D. Sun, X. Gan, L. Liu, Y. Yang, D. Ding, W. Li, J. Jiang, W. Ding, L. Zhao, G. Hou, J. Yu, J. Wang, F. Yang, S. Yuan, W. Zhou, Cell Death Dis. 2022, 13(5), 446. ; J. P. Cerapio, A. Marchio, L. Cano, I. López, J. J. Fournié, B. Régnault, S. Casavilca‐Zambrano, E. Ruiz, A. Dejean, S. Bertani, P. Pineau, Oncotarget 2021, 12(5), 475. ; C. Butler, S. Sprowls, G. Szalai, T. Arsiwala, P. Saralkar, B. Straight, S. Hatcher, E. Tyree, M. Yost, Gene 2020, 13(6), 100775. ; K. B. Chiappinelli, S. B. Baylin, J. Clin. Invest. 2022, 132(14), e160186. ; Y. Yuan, J. Zhang, X. Qi, S. Li, G. Liu, S. Siddhanta, I. Barman, X. Song, M. T. McMahon, J. W. M. Bulte, Nat. Mater. 2019, 18(12), 1376. ; P. Chaiyawat, N. Sirikaew, P. Budprom, J. Klangjorhor, A. Phanphaisarn, P. Teeyakasem, J. Settakorn, D. Pruksakorn, J. Bone Oncol. 2020, 25, 100321. ; Y.‐H. Chu, Y.‐C. Huang, P.‐Y. Chiu, W.‐H. Kuo, Y.‐R. Pan, Y.‐T. Kuo, R.‐H. Wang, Y.‐C. Kao, Y.‐H. Wang, Y.‐F. Lin, K. T. Lin, iScience 2023, 26(5), 106597. ; K. Minami, Y. Shinsato, M. Yamamoto, H. Takahashi, S. Zhang, Y. Nishizawa, S. Tabata, R. Ikeda, K. Kawahara, K. Tsujikawa, K. Chijiiwa, K. Yamada, S. Akiyama, S. Pérez‐Torras, M. Pastor‐Anglada, T. Furukawa, T. Yasuo, J. Pharmacol. Sci. 2015, 127(3), 319. ; V. L. Damaraju, D. Mowles, S. Yao, A. Ng, J. D. Young, C. E. Cass, Z. Tong, Nucleosides Nucleotides Nucleic Acids 2012, 31(3), 236. ; C. A. Koczor, R. A. Torres, W. Lewis, Expert Opin. Drug Metab. Toxicol. 2012, 8(6), 665. ; L. Gailhouste, L. C. Liew, K. Yasukawa, I. Hatada, Y. Tanaka, H. Nakagama, T. Ochiya, Mol. Ther. 2018, 26(7), 1840. ; L. Gailhouste, L. C. Liew, I. Hatada, H. Nakagama, T. Ochiya, Cell Death Dis. 2018, 9(5), 468. ; S. S. Panchal, S. B. Ghatak, A. B. Jha, R. Onattu, Environ. Toxicol. Pharmacol. 2017, 56, 86. ; S. Jiang, World J. Gastroenterol. 2012, 18(22), 2867. ; C. L. Zhang, T. Zeng, X. L. Zhao, L. H. Yu, Z. P. Zhu, K. Q. Xie, Int. J. Biol. Sci. 2012, 8(3), 363. ; U. Latief, H. Husain, D. Mukherjee, R. Ahmad, J. Basic Appl. Zool. 2016, 76, 31. ; B. N. Singh, B. R. Singh, B. K. Sarma, H. B. Singh, Chem. Biol. Interact. 2009, 181(1), 20. ; L. Masha, S. Peerbhai, D. Boone, F. Shobayo, A. Ghotra, B. Akkanti, Y. Zhao, I. Banjac, I. D. Gregoric, B. Kar, ASAIO J. 2019, 65(8), 812. ; B. I. Carr, V. Guerra, E. G. Giannini, F. Farinati, F. Ciccarese, G. Ludovico Rapaccini, M. Di Marco, L. Benvegnù, M. Zoli, F. Borzio, E. Caturelli, M. Chiaramonte, F. Trevisani, Semin. Oncol. 2014, 41(2), 252. ; J. M. Kim, C. H. D. Kwon, J.‐W. Joh, J. B. Park, J. S. Ko, J. H. Lee, S. J. Kim, C.‐K. Park, World J. Surg. Oncol. 2013, 11(1), 40. ; C.‐W. Huang, T.‐H. Wu, H.‐Y. Hsu, K.‐T. Pan, C.‐W. Lee, S.‐W. Chong, S.‐F. Huang, S.‐E. Lin, M.‐C. Yu, S.‐M. Chen, J. Pers. Med. 2022, 12(4), 518. ; P. Pancoska, M. De Giorgio, S. Fagiuoli, B. I. Carr, Dig. Dis. Sci. 2011, 56(10), 3078. ; P. C. Hart, I. M. Rajab, M. Alebraheem, L. A. Potempa, Front. Immunol. 2020, 11, 595835. ; W. Chen, J. B. Wang, C. C. Abnet, S. M. Dawsey, J. H. Fan, L. Y. Yin, J. Yin, P. R. Taylor, Y. L. Qiao, N. D. Freedman, Cancer Epidemiol. Biomarkers Prev. 2015, 24(2), 386. ; E. Poggiali, D. Zaino, P. Immovilli, L. Rovero, G. Losi, A. Dacrema, M. Nuccetelli, G. B. Vadacca, D. Guidetti, A. Vercelli, A. Magnacavallo, S. Bernardini, C. Terracciano, Clin. Chim. Acta 2020, 509, 135. ; A. Comandatore, M. Franczak, R. T. Smolenski, L. Morelli, G. J. Peters, E. Giovannetti, Semin. Cancer Biol. 2022, 86, 93. ; R. Liu, J. Cao, X. Gao, J. Zhang, L. Wang, B. Wang, L. Guo, X. Hu, Z. Wang, Tumor Biol. 2016, 37(10), 14083. ; L. Dercle, S. Ammari, E. Roblin, A. Bigorgne, S. Champiat, L. Taihi, A. Plaian, S. Hans, S. Lakiss, L. Tselikas, M. Rouanne, E. Deutsch, L. H. Schwartz, M. Gönen, J. Flynn, C. Massard, J. C. Soria, C. Robert, A. Marabelle, Eur. J. Cancer 2022, 177, 80. ; M. Ghahartars, S. Abtahi, Z. Zeinali, M. J. Fattahi, A. Ghaderi, Iran. Biomed. J. 2021, 25(2), 88. ; Y. Zeng, S. Lian, D. Li, X. Lin, B. Chen, H. Wei, T. Yang, Biomed. Pharmacother.2017, 95, 1868. ; S. Chanda, U. B. Dasgupta, D. Guhamazumder, M. Gupta, U. Chaudhuri, S. Lahiri, S. Das, N. Ghosh, D. Chatterjee, Toxicol. Sci 2006, 89(2), 431. ; R. Hill, M. Rabb, P. A. Madureira, D. Clements, S. A. Gujar, D. M. Waisman, C. A. Giacomantonio, P. W. K. Lee, Cell Death Dis. 2013, 4(9), e791. ; G. E. Adeleke, O. A. Adaramoye, J. Biochem. Mol. Toxicol. 2021, 35(11), e22901. ; P. K. S. Mahalingaiah, L. Ponnusamy, K. P. Singh, J. Cell. Physiol. 2015, 230(8), 1916. ; A. V. Snezhkina, A. V. Kudryavtseva, O. L. Kardymon, M. V. Savvateeva, N. V. Melnikova, G. S. Krasnov, A. A. Dmitriev, Oxid. Med. Cell. Longevity 2019, 2019, 6175804. ; F. U. Vaidya, A. S. Chhipa, N. Sagar, C. Pathak, in Role of Oxidative Stress in Pathophysiology of Diseases (Eds: P. K. Maurya, K. Dua), Springer, Singapore 2020, p. 229. ; C. Leonel, G. B. Gelaleti, B. V. Jardim, M. G. Moschetta, V. R. Regiani, J. G. Oliveira, D. A. Zuccari, BMC Vet. Res. 2014, 10(1), 49. ; N. Subhapradha, V. Shanmugam, A. Shanmugam, Carbohydr. Polym. 2017, 171, 18. ; N. Bhatia, B. Singh, A. Koul, Hepatoma Res. 2018, 4(9), 1. ; H. Younus, Int. J. Health Sci. 2018, 12(3), 88. ; G. Ramakrishnan, H. R. B. Raghavendran, R. Vinodhkumar, T. Devaki, Chem. Biol. Interact. 2006, 161(2), 104. ; S. Gaweł, M. Wardas, E. Niedworok, P. Wardas, Wiad. Lek. 2004, 57(9), 453. Grant Information: Nirma University Contributed Indexing: Keywords: DNMT1; gemcitabine; hepatocellular carcinoma; olsalazine Substance Nomenclature: 0W860991D6 (Deoxycytidine) ; 0 (Gemcitabine) ; EC 2.1.1.37 (DNA (Cytosine-5-)-Methyltransferase 1) ; EC 2.1.1.37 (DNMT1 protein, human) Entry Date(s): Date Created: 20240527 Date Completed: 20240527 Latest Revision: 20240527 Update Code: 20240527

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Olsalazine pretreatment augments chemosensitivity of gemcitabine in hepatocellular carcinoma.